Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.51 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3766135 | 0.98 | OPRL1 (0.61) | OPRL1OPRM1OPRK1CHRM1C5AR1 | |
| SCHEMBL13005817 | 0.89 | OPRL1 (0.60) | OPRL1OPRM1OPRK1CHRM1C5AR1 | |
| SCHEMBL18729423 | 0.81 | OPRL1 (0.61) | OPRL1OPRM1OPRK1C5AR1EGLN1 | |
| SCHEMBL4725264 | 0.76 | OPRL1 (0.49) | OPRL1OPRM1OPRK1HRH3ALDH1A1 | |
| SCHEMBL3767750 | 0.76 | OPRM1 (0.44) | OPRL1OPRM1OPRK1CHRM1C5AR1 | |
| SCHEMBL3771547 | 0.74 | OPRK1 (0.54) | OPRL1OPRM1OPRK1C5AR1EGLN1 | |
| SCHEMBL3738796 | 0.74 | OPRK1 (0.54) | OPRL1OPRM1OPRK1C5AR1EGLN1 | |
| SCHEMBL14608881 | 0.74 | OPRK1 (0.54) | OPRL1OPRM1OPRK1C5AR1EGLN1 | |
| SCHEMBL13480023 | 0.74 | OPRL1 (1.00) | OPRL1OPRM1OPRK1C5AR1EGLN1 | |
| SCHEMBL20989214 | 0.73 | OPRL1 (0.69) | OPRL1OPRM1OPRK1C5AR1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| EP-1909797-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | OPRL1 347/4885OPRM1 743/4885OPRK1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.